First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Total Liabilities
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued total liabilities. Based on the latest financial reports, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) has total liabilities worth $33.11 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of First Tracks Biotherapeutics, Inc. Ordin to evaluate the company's liquid asset resilience ratio.
Total Liabilities of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
Total liabilities of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024. This chart illustrates how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's total liabilities have evolved over time, based on quarterly financial data. Explore First Tracks Biotherapeutics, Inc. Ordin (TRAXV) investment intensity to see how much of total assets are deployed in long-term investments.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Competitors by Total Liabilities
The table below lists competitors of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Qianjiang Biochemical Co Ltd
SHG:600796
|
China | CN¥3.71 Billion |
|
Invesco Municipal Opportunity Trust
NYSE:VMO
|
USA | $393.53 Million |
|
Betterware de México, S.A.P.I. de C.V.
NYSE:BWMX
|
USA | $12.60 Billion |
|
Anhui Ronds Science & Technology Inc Co
SHG:688768
|
China | CN¥295.13 Million |
|
Cass Information Systems Inc
NASDAQ:CASS
|
USA | $2.29 Billion |
|
Dongrui Food Group Co Ltd
SHE:001201
|
China | CN¥2.81 Billion |
|
Echo Investment SA
WAR:ECH
|
Poland | zł4.92 Billion |
|
HEG Limited
NSE:HEG
|
India | Rs-47.58 Billion |
Liability Composition Analysis (2023–2024)
This chart breaks down First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TRAXV asset base.
Liquidity & Leverage Metrics
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Total Liabilities Ratios Explained
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
The table below shows the annual total liabilities of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $50.30 Million | +46.80% |
| 2023-12-31 | $34.26 Million | -- |
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more